Daito Pharmaceutical Co., Ltd.

Daito Pharmaceutical Co., Ltd. is a prominent Japanese pharmaceutical company specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished dosage forms (formulations). Founded in 1942 and headquartered in Toyama, the company operates as a major Contract Development and Manufacturing Organization (CDMO) and a provider of generic drugs. Daito is known for its integrated manufacturing system that covers the entire process from API synthesis to final formulation, including tablets, capsules, and granules. The company serves a global client base, including major pharmaceutical firms such as Takeda, Astellas, and Eisai. Daito maintains high quality standards with facilities that are compliant with Japanese GMP, US cGMP (FDA), and EU GMP guidelines. In 2024, the company launched its 'Daito Transformation Plan 2027' (DTP2027) to streamline existing businesses, expand its international presence (particularly in China), and enter new business areas to enhance long-term corporate value.